Upchurch W, Iaizzo P
Exp Biol Med (Maywood). 2022; 247(7):584-597.
PMID: 35068214
PMC: 9014520.
DOI: 10.1177/15353702211070535.
Su I, Wang P, Chen C, Huang H, Day Y
Tzu Chi Med J. 2021; 33(4):399-405.
PMID: 34760638
PMC: 8532588.
DOI: 10.4103/tcmj.tcmj_271_20.
Oliveira P, Salvador G, Marchi-Salvador D
J Med Cases. 2021; 11(12):379-387.
PMID: 34434350
PMC: 8383552.
DOI: 10.14740/jmc3577.
Laitano O, Murray K, Leon L
Sports Med. 2020; 50(9):1581-1592.
PMID: 32632746
DOI: 10.1007/s40279-020-01318-4.
Schneiderbanger D, Johannsen S, Roewer N, Schuster F
Ther Clin Risk Manag. 2014; 10:355-62.
PMID: 24868161
PMC: 4027921.
DOI: 10.2147/TCRM.S47632.
Malignant hyperthermia.
Kim D
Korean J Anesthesiol. 2012; 63(5):391-401.
PMID: 23198031
PMC: 3506847.
DOI: 10.4097/kjae.2012.63.5.391.
The genetics of malignant hyperthermia.
Ball S, Johnson K
J Med Genet. 1993; 30(2):89-93.
PMID: 8383206
PMC: 1016259.
DOI: 10.1136/jmg.30.2.89.
C1840-T mutation in the human skeletal muscle ryanodine receptor gene: frequency in northern German families susceptible to malignant hyperthermia and the relationship to in vitro contracture response.
Steinfath M, Singh S, Scholz J, Becker K, Lenzen C, Wappler F
J Mol Med (Berl). 1995; 73(1):35-40.
PMID: 7633940
DOI: 10.1007/BF00203617.
Effect of temperature, time and fascicle size on the caffeine contracture test.
Britt B, Endrenyi L, Scott E, Frodis W
Can Anaesth Soc J. 1980; 27(1):1-11.
PMID: 7353184
DOI: 10.1007/BF03006840.
Comparison of the caffeine skinned fibre tension (CSFT) test with the caffeine-halothane contracture (CHC) test in the diagnosis of malignant hyperthermia.
Britt B, Frodis W, Scott E, Clements M, Endrenyi L
Can Anaesth Soc J. 1982; 29(6):550-62.
PMID: 7139394
DOI: 10.1007/BF03007740.
Malignant hyperpyrexia.
Keaney N, Ellis F
Br Med J. 1971; 4(5778):49.
PMID: 5096894
PMC: 1799204.
DOI: 10.1136/bmj.4.5778.49-a.
Screening for malignant hyperpyrexia.
Ellis F, Keaney N, Harriman D, SUMNER D, Tyrrell J, Hargreaves J
Br Med J. 1972; 3(5826):559-61.
PMID: 5069639
PMC: 1785894.
DOI: 10.1136/bmj.3.5826.559.
Identification of susceptibility to malignant hyperpyrexia.
Moulds R, Denborough M
Br Med J. 1974; 2(5913):245-7.
PMID: 4827071
PMC: 1610555.
DOI: 10.1136/bmj.2.5913.245.
Malignant hyperpyrexia. Further muscle studies in asymptomatic carriers identified by creatinine phosphokinase screening.
Isaacs H, BARLOW M
J Neurol Neurosurg Psychiatry. 1973; 36(2):228-43.
PMID: 4708457
PMC: 1083559.
DOI: 10.1136/jnnp.36.2.228.
Central-core disease and malignant hyperpyrexia.
Harriman D, Ellis F
Br Med J. 1973; 1(5852):545-6.
PMID: 4692683
PMC: 1588736.
DOI: 10.1136/bmj.1.5852.545-a.
Histopathological and neuropharmacological aspects of malignant hyperpyrexia.
Ellis F, Keaney N, Harriman D
Proc R Soc Med. 1973; 66(1 Pt 1):66-7.
PMID: 4690061
PMC: 1644370.
Clinical and genetic aspects of malignant hyperpyrexia.
Tyrrell J, SUMNER D
Proc R Soc Med. 1973; 66(1 Pt 1):63-6.
PMID: 4690060
PMC: 1644366.
Procaine in malignant hyperpyrexia.
Moulds R, Denborough M
Br Med J. 1972; 4(5839):526-8.
PMID: 4642792
PMC: 1788768.
DOI: 10.1136/bmj.4.5839.526.
Malignant hyperthermia: molecular defects in membrane permeability.
Cheah K, Cheah A
Experientia. 1985; 41(5):656-61.
PMID: 3888661
DOI: 10.1007/BF02007707.
Porcine malignant hyperthermia susceptibility: hypersensitive calcium-release mechanism of skeletal muscle sarcoplasmic reticulum.
OBrien P
Can J Vet Res. 1986; 50(3):318-28.
PMID: 3742367
PMC: 1255220.
